Literature DB >> 23883161

Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients.

Roberta Gualtierotti1, Annalisa Zoppi, Amedeo Mugellini, Giuseppe Derosa, Angela D'Angelo, Roberto Fogari.   

Abstract

BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used for reducing pain and other symptoms in osteoarthritis (OA). NSAIDs have been associated with an increase in blood pressure (BP) in both normotensive and hypertensive individuals and a blunting effect on various anti-hypertensive medications. Acetaminophen effects on anti-hypertensive treatment, instead, are still a matter of debate.
OBJECTIVES: To assess the effect of naproxen versus acetaminophen on ramipril, valsartan and aliskiren therapy in hypertensive patients with OA in a double-blind, cross-over study, by measuring clinic, ambulatory BP and heart rate (HR).
RESULTS: One hundred seventy four patients were randomly treated with ramipril, valsartan or aliskiren for 8 weeks and 135 patients with normalized BP were randomized to receive naproxen or acetaminophen for 2 weeks. Naproxen significantly increased clinic and ambulatory systolic/diastolic BP (SBP/DBP) values in patients treated with ramipril (p < 0.01) or valsartan (p < 0.05), but did not affect aliskiren effects. Also acetaminophen slightly but significantly affected clinic and ambulatory SBP/DBP in all three groups and, surprisingly, it also produced a slight increase in HR (+3.1, +3.3 and +3.4 b/min day-time HR values, for ramipril, valsartan and aliskiren, respectively; p < 0.05).
CONCLUSIONS: Both naproxen and acetaminophen can affect anti-hypertensive therapy with ramipril, valsartan or aliskiren with a different extent. When acetaminophen is chosen for OA management in subjects with hypertension, patients should be evaluated as carefully as when traditional NSAIDs are given.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883161     DOI: 10.1517/14656566.2013.816286

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

Review 1.  Polypharmacy in Older Adults With Hypertension: A Comprehensive Review.

Authors:  Bertrand N Mukete; Keith C Ferdinand
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-27       Impact factor: 3.738

2.  Chronic Pain: How Challenging Are DDIs in the Analgesic Treatment of Inpatients with Multiple Chronic Conditions?

Authors:  Klarissa Siebenhuener; Emmanuel Eschmann; Alexander Kienast; Dominik Schneider; Christoph E Minder; Reinhard Saller; Lukas Zimmerli; Jürg Blaser; Edouard Battegay; Barbara M Holzer
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

Review 3.  Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis.

Authors:  Roberta Gualtierotti; Nicola Ughi; Giovanni Marfia; Francesca Ingegnoli
Journal:  Rheumatol Ther       Date:  2017-07-27

Review 4.  Safety of Paracetamol in Osteoarthritis: What Does the Literature Say?

Authors:  Philip G Conaghan; Nigel Arden; Bernard Avouac; Alberto Migliore; René Rizzoli
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

5.  Comorbidity of asthma and hypertension may be mediated by shared genetic dysregulation and drug side effects.

Authors:  Olga Zolotareva; Olga V Saik; Cassandra Königs; Elena Yu Bragina; Irina A Goncharova; Maxim B Freidin; Victor E Dosenko; Vladimir A Ivanisenko; Ralf Hofestädt
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

Review 6.  Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy.

Authors:  Roberta Gualtierotti; Francesco Tafuri; Sara Arcudi; Pier Luigi Solimeno; Jacopo Acquati; Laura Landi; Flora Peyvandi
Journal:  Pain Ther       Date:  2022-01-12

7.  The Risk of Drug-Drug Interactions with Paracetamol in a Population of Hospitalized Geriatric Patients.

Authors:  Lykke Ida Kaas Oldenburg; Kim Peder Dalhoff; Luana Østerdal Sandoval; Charlotte Vermehren
Journal:  J Pharm (Cairo)       Date:  2020-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.